GEORGE A SCANGOS
CIK 1202102 · President and CEO · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$69.54M
Companies
6
Total Filings
204
Lifetime Open-Market Net
-$56.60M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYGR | Director | — | $3.00 | — | $0 | 5 | 2026-06-11 |
| A | Director | 40,693 | $140.30 | $5.71M | $0 | 15 | 2026-03-23 |
| VIR | Director | 1,296,509 | $8.64 | $11.20M | -$3.09M | 14 | 2025-02-25 |
| EXEL | Director | 723,680 | $55.33 | $40.04M | -$24.48M | 92 | 2020-05-20 |
| BIIB | Chief Executive Officer | 60,157 | $209.23 | $12.59M | -$29.10M | 64 | 2016-07-22 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 33,188 | — | — | $75.2K | 7 | 2010-05-28 |
Recent Filings · Page 15 of 21
204 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-07-21 | BIIB | Sell (S) | −12,347 | -$1.32M | EDGAR |
| 2011-07-19 | BIIB | Mixed | +3,639 | -$1.84M | EDGAR |
| 2011-05-20 | EXEL | Grant (A) | — | $0 | EDGAR |
| 2011-02-11 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2010-07-19 | BIIB | Grant (A) | +63,165 | $0 | EDGAR |
| 2010-05-28 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-11 | EXEL | Grant (A) | — | $0 | EDGAR |
| 2009-05-29 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-03-02 | EXEL | Grant (A) | — | $0 | EDGAR |
| 2008-12-18 | EXEL | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.